Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB (NASDAQ: BIOA B) hosted its Capital Markets Day 2025, outlining ambitious plans to become Sweden's next major pharmaceutical company by 2030. The company's strategy focuses on expanding its pipeline across brain diseases, securing global partnerships, and establishing Leqembi® for Alzheimer's treatment in the Nordic region. Key presentations covered financial outlook, with expected profitability from 2025, R&D strategy featuring their BrainTransporter™ technology enabling up to 70x greater brain exposure for antibodies, and updates on Leqembi® and exidavnemab programs. The event highlighted BioArctic's commitment to innovation in neurology, particularly their progress in Alzheimer's treatment and development of therapies for alpha-synuclein diseases including Parkinson's, Multiple System Atrophy, and Lewy body dementia.

Barrick Mining Corporation (NYSE:B) is facing a critical situation in Mali as the government attempts to take control of the Loulo-Gounkoto mining complex. A court ruling is expected on June 2 following Barrick's opposition to the government's request for provisional administration. The conflict includes the unlawful detention of Barrick employees for over five months and the blockage of gold exports from the complex. Despite these challenges, Barrick continues to support its workforce by maintaining wage payments. The company has initiated international arbitration proceedings while seeking dialogue with Mali's government, emphasizing its three-decade presence in the country and significant contributions to Mali's economy. Barrick maintains that the government's actions violate both Malian law and existing agreements, undermining the partnership principles between governments and long-term investors.

Barrick Mining Corporation (NYSE:B) has published its 2024 Sustainability Report titled "Beyond the Horizon," showcasing its commitment to the UN's Sustainable Development Goals 2030. Since its 2019 merger, Barrick has distributed over $100 billion in economic value across host countries and invested $200 million through Community Development Committees. The company maintains 97% local employment and spent $7.1 billion with local suppliers in 2024. Barrick has updated its greenhouse gas emissions reduction roadmap while maintaining its Net Zero by 2050 commitment. The company has implemented a new site-level SDG performance framework to track development indicators such as clean water, education, and healthcare. Environmental achievements include 85% water reuse/recycling and ongoing renewable energy investments in Pakistan, Argentina, and the DRC.

BioArctic AB (BIOA) announced that its partner Eisai projects Leqembi® sales to reach JPY 76.5 billion (approximately SEK 5.1 billion) for fiscal year 2025 (April 2025 - March 2026). This represents a 73% growth compared to the previous year and is expected to generate around SEK 510 M in royalty for BioArctic.

Eisai leads Leqembi's development and regulatory submissions globally, with both Eisai and Biogen co-commercializing the product. BioArctic maintains rights to commercialize Leqembi in the Nordic region in partnership with Eisai, and both companies are preparing for joint commercialization in the region.

ETQ's second annual Pulse of Quality in Manufacturing Survey reveals persistent manufacturing challenges in 2025. Key findings show 70% of U.S. manufacturers face labor shortages, with 88% reporting impact on product quality. The survey indicates 75% of organizations experienced product recalls in the past five years, with 48% of recalls costing between $10-49.99 million.

The study highlights increasing AI adoption in manufacturing, with 49% planning implementation within two years and 33% already using it. AI applications focus on document processing (46%), core process automation (47%), and defect detection (45%). Additionally, 60% of respondents plan to increase quality-related spending in 2025, investing in generative AI, automated quality management tools, and predictive analytics.

BioArctic AB (Nasdaq Stockholm: BIOA B) has announced it will release its Q1 2025 financial report on Wednesday, May 21, 2025, at 08:00 CET. Following the report's publication, the company will host an audiocast with teleconference in English at 09:30 CET.

CEO Gunilla Osswald and CFO Anders Martin-Löf will present the quarterly results and conduct a Q&A session. Participants can join via webcast or teleconference, with options for submitting questions either in writing through the webcast or verbally via the teleconference. The presentation will later be available on-demand through BioArctic's corporate website.

Barrick Mining Corporation (NYSE:B, TSX:ABX) has begun trading under the new single-letter ticker symbol 'B' on the New York Stock Exchange. To mark this milestone, CEO Mark Bristow rang The Opening Bell® at the NYSE. The company maintains its 'ABX' symbol on the Toronto Stock Exchange.

As a leading global gold and copper mining company, Barrick operates six Tier One gold mines and is expanding its copper operations. The company's strategy combines the stability of gold with copper's growth potential, positioning itself to benefit from increasing global electrification and infrastructure demand. Key development projects include the Pueblo Viejo expansion, Fourmile gold project in Nevada, and the Reko Diq project featuring both copper and gold deposits.

Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following its regular board meeting on May 7, 2025. The company will distribute a dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on June 6, 2025, to shareholders who are on record as of the market close on May 23, 2025.

BioArctic AB (BIOA) has received regulatory approval in Spain and Poland to expand its EXIST Phase 2a study of exidavnemab to include Multiple System Atrophy (MSA) patients. The study will now add 12 MSA patients to the existing 24 Parkinson's Disease participants.

Exidavnemab is a monoclonal antibody targeting alpha-synuclein aggregates, being developed as a potential disease-modifying treatment for neuronal synuclein diseases. The study will evaluate safety, tolerability, and various biomarkers in plasma, cerebrospinal fluid, and through digital measurements.

MSA is described as a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems, with no current cure or treatment to slow progression. The condition impacts basic functions including breathing, digestion, and bladder control.